Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Medical uses  




2 Adverse effects  




3 Pharmacokinetics and pharmacodynamics  




4 Regulatory Information  




5 Commercial production  




6 See also  




7 References  




8 External links  













Halazepam






●Cymraeg
 ●Deutsch
 ●Español
 ●فارسی
 ●Français
 ●Hrvatski
 ●Italiano
 ●日本語
 ●Polski
 ●Português
 ●Română
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Suomi
 ●Svenska
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Halazepam
Clinical data
Other names9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa684001
Pregnancy
category
  • ?
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • CA: Schedule IV
  • DE: Prescription only (Anlage III for higher doses)
  • US: Schedule IV
    • Pharmacokinetic data
    MetabolismHepatic
    Elimination half-life14 hours (halazepam), 50–100 hours (metabolites).
    ExcretionRenal
    Identifiers

    • 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.041.281 Edit this at Wikidata
    Chemical and physical data
    FormulaC17H12ClF3N2O
    Molar mass352.74 g·mol−1
    3D model (JSmol)

    • FC(F)(CN1C(CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3)=O)F

    • InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 checkY

    • Key:WYCLKVQLVUQKNZ-UHFFFAOYSA-N checkY

      (verify)

    Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[2] Alapryl in Spain,[3] and Pacinone in Portugal.[4]

    Medical uses[edit]

    Halazepam was used for the treatment of anxiety.[2]

    Adverse effects[edit]

    Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[2]

    Pharmacokinetics and pharmacodynamics[edit]

    Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:[5]

    Onset of action Intermediate to slow
    Plasma half life 14 hr for parent drug and 30-100 hr for its metabolite
    Peak plasma levels 1-3 hr for parent drug and 3-6 hf for its metabolite
    Metabolism Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
    Excretion Excreted through kidneys
    Protein binding 98% bound to plasma protein

    Regulatory Information[edit]

    Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[6]

    Commercial production[edit]

    Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[2]

    See also[edit]

    References[edit]

    1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  • ^ a b c d "halazepam". Drugs.com. Retrieved December 11, 2014.
  • ^ "Alapryl". Drugs.com. Retrieved December 11, 2014.
  • ^ "Pacinone". Drugs.com. Retrieved December 11, 2014.
  • ^ Sellers EM (1998). "Antianxiety agents: benzodiazepine derivatives". In Quitkin FM, et al. (eds.). Current Psychotherapeutic Drugs (2nd ed.). Washington: American Psychiatric Press. p. 166. ISBN 978-0-88048-994-2.
  • ^ "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Regulations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.

    • External links[edit]


    Stub icon

    This sedative-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Halazepam&oldid=1231827900"
    Categories: 
    ●Withdrawn drugs
     ●Benzodiazepines
     ●Chloroarenes
     ●Lactams
     ●Trifluoromethyl compounds
     ●Sedative stubs
     Hidden categories: 
    ●CS1 Brazilian Portuguese-language sources (pt-br)
     ●Articles with short description
     ●Short description matches Wikidata
     ●ECHA InfoCard ID from Wikidata
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 30 June 2024, at 13:48 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki